Literature DB >> 3339904

Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry.

H Z Winkler1, L M Rainwater, R P Myers, G M Farrow, T M Therneau, H Zincke, M M Lieber.   

Abstract

Flow cytometric analysis of nuclear DNA ploidy pattern was performed on 91 samples of prostatic adenocarcinoma from patients with stage D1 disease (metastatic deposits in pelvic lymph nodes). All patients had undergone radical retropubic prostatectomy and bilateral pelvic lymphadenectomy. Clinical follow-up ranged from 5 to 19 years. Nuclei were extracted from paraffin-embedded archival material. Isolated nuclei were stained with propidium iodide. The DNA ploidy pattern was diploid (normal) in 42% of tumors, tetraploid in 45%, and distinctly aneuploid in 13%. Only 15% of DNA diploid tumors progressed locally or systemically, whereas 75% of tumors with an abnormal DNA ploidy pattern (tetraploid or aneuploid) subsequently progressed (P less than 0.0001). Among low-grade tumors, ploidy analysis detected a subgroup associated with a poor prognosis; among high-grade tumors, a subgroup associated with a favorable prognosis was detected. None of the patients with a DNA diploid tumor died of prostatic cancer during the period of observation. In contrast, 43% of patients with DNA tetraploid tumors and 44% of those with DNA aneuploid tumors had died of prostatic cancer 10 years after surgical treatment (P less than 0.001). Determination of nuclear DNA ploidy pattern by flow cytometry provides objective, highly significant, prognostic information for patients with stage D1 prostatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3339904     DOI: 10.1016/s0025-6196(12)64942-8

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  8 in total

Review 1.  Molecular and cellular markers for metastatic prostate cancer.

Authors:  C W Rinker-Schaeffer; W B Isaacs; J T Isaacs
Journal:  Cancer Metastasis Rev       Date:  1993-03       Impact factor: 9.264

2.  Carcinoma of the Prostate: Screening and investigative techniques and treatments.

Authors:  B J Donnelly
Journal:  Can Fam Physician       Date:  1991-04       Impact factor: 3.275

Review 3.  Molecular and genetic prognostic factors of prostate cancer.

Authors:  Arnab Chakravarti; Gary Guotang Zhai
Journal:  World J Urol       Date:  2003-08-09       Impact factor: 4.226

4.  DNA-ploidy, G2M-fractions and prognosis of stages B and C prostate carcinoma.

Authors:  J G Müller; S Demel; M P Wirth; A Manseck; H G Frohmüller; H A Müller
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

5.  Automated image analysis DNA cytometry in testicular cancer.

Authors:  R A Bürger; U Witzsch; H Engel; D Potratz; M Stöckle
Journal:  Urol Res       Date:  1994

6.  The value of prognostic factors in prostatic cancer.

Authors:  J Schubert; S Kowalik
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

Review 7.  Tissue biomarkers for prostate cancer radiation therapy.

Authors:  P T Tran; R K Hales; J Zeng; K Aziz; T Salih; R P Gajula; S Chettiar; N Gandhi; A T Wild; R Kumar; J M Herman; D Y Song; T L DeWeese
Journal:  Curr Mol Med       Date:  2012-07-01       Impact factor: 2.222

8.  Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy.

Authors:  T Visakorpi; O P Kallioniemi; I Y Paronen; J J Isola; A I Heikkinen; T A Koivula
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.